Unified Patents v. Genzyme Corporation

Unified Patents, a member-based organization dedicated to deterring non-practicing entities (NPEs) and improving patent quality, initiated an inter partes review (IPR) challenging a patent application owned by Genzyme Corporation. Genzyme, a subsidiary of Sanofi, is an American biotechnology company based in Cambridge, Massachusetts, known for developing transformative therapies and diagnostic products, particularly in areas such as rare genetic disorders, renal diseases, orthopedics, cancer, transplant, and immune diseases. The IPR, designated IPR2026-00149, specifically challenged patent application number 18/506,853, which is categorized under Technology Center 1600 (Biotechnology and Organic Chemistry) at the USPTO. The patent number "12013326" provided in the case metadata does not correspond to a granted U.S. patent identifiable through public databases, and thus a specific technical sketch for that number cannot be provided.

The case was brought before the United States Patent and Trademark Office's (USPTO) Patent Trial and Appeal Board (PTAB), the administrative body responsible for conducting IPRs. On May 6, 2026, the PTAB denied institution of the IPR petition. This denial means the Board found that Unified Patents did not demonstrate a reasonable likelihood of prevailing on at least one challenged claim, or it exercised its discretion not to institute the review. The "Institution Denied" outcome is noteworthy, particularly in the context of recent policy shifts by the USPTO Director, who, in March 2026, issued new discretionary factors for IPR institution decisions, including considerations of domestic manufacturing presence, investment in American manufacturing, and small business status. While the specific grounds for the discretionary denial in this case are not publicly detailed, the outcome underscores the PTAB's significant gatekeeping role in post-grant proceedings and Unified Patents' ongoing engagement in challenging patent validity.

The provided case, Unified Patents v. Genzyme Corporation, IPR2026-00149, is an Inter Partes Review (IPR) proceeding before the Patent Trial and Appeal Board (PTAB) of the USPTO, not a patent infringement litigation in a district court. Therefore, many of the requested litigation milestones such as initial pleadings, Markman hearings, discovery, and trial events do not apply in the same manner.

Here are the key legal developments and outcome for this IPR proceeding:

• Filing of Petition (2026): Unified Patents filed an Inter Partes Review petition, IPR2026-00149, challenging the validity of US Patent 12013326. The case was filed in 2026.
• Institution Decision (2026-05-06): The PTAB issued a decision on May 6, 2026, denying institution of the Inter Partes Review.
• Outcome: The IPR proceeding was terminated as a result of the denial of institution, meaning the PTAB did not proceed to a full review of the challenged patent claims.

As this was an IPR that did not proceed past the institution stage, there were no district court patent infringement litigation filings, Markman claim constructions, extensive discovery, or trial events associated with this specific IPR case. The PTAB's decision to deny institution effectively concluded the IPR challenge against US Patent 12013326 by Unified Patents in this proceeding.

Counsel of Record for Plaintiff Sarepta Therapeutics, Inc.

The plaintiff in IPR2026-00149, challenging U.S. Patent No. 12013326, is Sarepta Therapeutics, Inc., not Unified Patents as originally indicated in the case metadata. Sarepta Therapeutics filed the inter partes review (IPR) petition against Genzyme Corporation's patent on November 25, 2025. The petition was denied institution by the Patent Trial and Appeal Board (PTAB) on May 6, 2026.

Based on reports regarding the filing of this IPR, the following attorneys represented Sarepta Therapeutics:

• Leah Watson
  • Role: Counsel
  • Firm: Venable LLP
  • Office Location: Likely Washington, D.C. or another Venable office specializing in intellectual property.
  • Relevant Experience: Co-authored an article on Sarepta's IPR filings against Genzyme's patents. Venable LLP has an Intellectual Property Litigation practice, and its attorneys have experience with inter partes review proceedings.
• Robert S. Schwartz, Ph.D.
  • Role: Counsel
  • Firm: Venable LLP
  • Office Location: Likely Washington, D.C. or another Venable office specializing in intellectual property.
  • Relevant Experience: Co-authored an article on Sarepta's IPR filings against Genzyme's patents, indicating involvement in biotechnology and pharmaceutical patent disputes. Venable LLP's BiologicsHQ.com platform suggests expertise in biologic patent disputes.

It is important to note that the provided case metadata inaccurately listed "Unified Patents" as the plaintiff. Public records and legal news confirm Sarepta Therapeutics, Inc. as the petitioner in IPR2026-00149.

Based on the available information, the counsel of record representing Genzyme Corporation in IPR2026-00149 is:

Donald Jackson (and associated attorneys)

• Role: Counsel for Patent Owner/Respondent
• Firm: Not explicitly specified in the available USPTO Patent Trial and Appeal Board (PTAB) Decisions Open Data Portal snippet for this specific IPR.
• Office Location: Not explicitly specified.
• One-line note on relevant patent litigation experience or notable past cases: The specific "Donald Jackson" identified in the PTAB record for IPR2026-00149 does not have his firm, office location, or detailed patent litigation experience for this particular representation readily available in the public search results. While other attorneys named Donald Jackson have extensive litigation backgrounds, their direct involvement in this specific IPR for Genzyme cannot be confirmed.

General Context on Genzyme's Patent Litigation Counsel:

Genzyme Corporation, a subsidiary of Sanofi, frequently relies on specialized intellectual property law firms for its complex patent litigation and PTAB proceedings within the biotechnology and pharmaceutical sectors. For instance, Williams & Connolly LLP has publicly stated that it represents "Roche/Genentech" in significant intellectual property matters, including patent litigation and inter partes review (IPR) proceedings. Their practice encompasses representing pharmaceutical companies in Hatch-Waxman and Biologics Price Competition and Innovation Act (BPCIA) litigation and they have experience with over 100 IPR proceedings for pharmaceutical clients. Therefore, it is plausible that attorneys from Williams & Connolly or a similar specialist firm may represent Genzyme in such proceedings.

It is worth noting a discrepancy in the provided case metadata versus some search results regarding the petitioner. The case metadata indicates "Unified Patents" as the plaintiff, while several search results identify "Sarepta Therapeutics" as having filed IPR2026-00149 against Genzyme's patent 12,013,326. Regardless of the petitioner's identity, Genzyme Corporation remains the Patent Owner/Respondent whose counsel is being identified.